Results 121 to 130 of about 1,085,795 (289)

A human T lymphocyte differentiation marker defined by monoclonal antibodies that block E-rosette formation. [PDF]

, 1981
F. D. Howard, J A Ledbetter, Jonathan P. Wong, C P Bieber, Edward B. Stinson, L A Herzenberg   +5 more
openalex   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Suppression of anti-drug antibody formation against coagulation factor VIII by oral delivery of anti-CD3 monoclonal antibody in hemophilia A mice. [PDF]

Cell Immunol, 2023
Bertolini TB, Herzog RW, Kumar SRP, Sherman A, Rana J, Kaczmarek R, Yamada K, Arisa S, Lillicrap D, Terhorst C, Daniell H, Biswas M.   +11 more
europepmc   +1 more source

The Story Behind “A Requirement for Two Cell Types for Antibody Formation in vitro†[PDF]

, 2014
Donald E. Mosier
openalex   +1 more source

Template Theories, the Rule of Parsimony, and Disregard for Irreproducibility—The Example of Linus Pauling’s Research on Antibody Formation [PDF]

, 2021
Ute Deichmann
openalex   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Anti-S1/RBD-Specific Antibody Formation After SARS-CoV-2 Vaccination in Elderly Rheumatoid Arthritis Patients: Single-Center Prospective Observational Study. [PDF]

J Korean Med Sci, 2023
Kang ES, Oh JS, Lee EJ, Hong S, Ahn SM, Ahn SM, Lee CK, Yoo B, Kim YG.   +8 more
europepmc   +1 more source

Increased cell cycle‐dependent staining of plant cells by the antibody MPM‐2 correlates with preprophase band formation [PDF]

, 1994
Todd E. Young, Jeremy S. Hyams, Clive Lloyd   +2 more
openalex   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Suppression of renal crystal formation, inflammation, and fibrosis by blocking oncostatin M receptor β signaling

Scientific Reports
Oncostatin M (OSM) has pleiotropic effects on various inflammatory diseases, including kidney stone disease. The prevalence of kidney stones has increased worldwide, despite recent therapeutic advances, due to its high recurrence rate, suggesting the ...
Ryusuke Deguchi, Tadasuke Komori, Shimpei Yamashita, Tomoko Hisaoka, Mizuki Kajimoto, Yasuo Kohjimoto, Isao Hara, Yoshihiro Morikawa   +7 more
doaj   +1 more source